ResMed Inc (RMD) exceeded analysts’ expectations in the first quarter, reporting a 34% year-over-year jump in adjusted EPS and 11% revenue growth. The company’s strong performance was driven by increased demand for sleep devices and software, as well as operational efficiency. Analyst William Blair maintains an Outperform rating, highlighting ResMed’s robust fundamentals and positive outlook.